September 6th 2025
Up to 2 million people in low- and lower-middle-income countries may gain access to the long-acting PrEP option under a three-year, no-profit agreement.
September 4th 2025
Implants of Tenofovir Alafenamide Could Provide Protection for 6 Months, Study Says
April 12th 2019Subcutaneous implants are 1 promising strategy to address suboptimal adherence to pre-exposure prophylaxis (PrEP) for HIV, and a recent in silico simulation examined pharmacokinetic profiles and safety of tenofovir alafenamide implants.
Read More